Innovation Pharmaceuticals Inc (IPIX)

[Ro the Bull]

Per my understanding, Brilacidin has long half life. That means it stays effective longer. The side effect issues with the Poly trials appear to be from a long term build up, or too high a dosing due to the long half life. This is why cellceutix is running the trials with smaller dosing and shorter dosing period. This is also why it's thought that it might be effective in eye and ear treatments as a topical, as it would stay on the surface and be effective longer.

Kevetrin has a very short half life. This means that it goes in, does its thing, and then doesn't seem to have time to stay in the system to cause adverse reactions.

If my understanding is incorrect, and someone with a more technical background wants to approach this, that'd be appreciated. Thanks!